Superficial basal cell carcinoma
Conditions
Interventions
Product Name: Capsaicin 0.05% Creme
Pharmaceutical Form: Cream
Pharmaceutical form of the placebo: Cream
Route of administration of the placebo: Cutaneous use
Pharmaceutical Form:
Sponsors
Peter Wolf MD, Department of Dermatology, Medical University of Graz
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion: 1) age > 18 years 2) patients with superficial basal cell carcinomas on trunk or extremities Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Exclusion: 1) severe general diseases or metastatic tumors 2) systemic immunosuppressive therapy 3) photosensitive skin diseases such as porphyria, Xeroderma pigmentosum or other diseases with defective repair mechanism DNA-repair 4) Autoimmundermatoses (Lupus erythemathodes, Dermatomyositis) 5) Antinuclear antibodies (ds-DNA, Ro/SSA und La/SSB) 6) Known allergy to drugs used in the study (Metvix®, Capsaicin 0,05%-Creme, Diprosicc) 7) pregnancy or lactation 8) coagulopathy or treatment with anticoagulant therapy (e.g. treatment with Marcoumar® oder Sintrom®) 9) Pigmented or sklerodermiform variant of basal cell carcinomas 10) Location of the basalioma in the face
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To test whether pretreatment of superficial basal cell carcinomas with capsaicin cream reduces neurogenic inflammation and pain during photodynamic treatment;Secondary Objective: ;Primary end point(s): Pain reaction Neuropeptide CGRP | — |
Countries
Austria
Outcome results
None listed